Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402863 | 0.83 | BCHE (0.46) | PDPK1MTORCYP2C19MAPTTMEM97 | |
| SCHEMBL12672520 | 0.83 | MEN1 (0.39) | PDPK1MTORCYP2C19MAPTSLC6A2 | |
| SCHEMBL21572017 | 0.83 | BCHE (0.44) | CYP2C19MAPTTMEM97SIGMAR1BCHE | |
| SCHEMBL10148633 | 0.81 | L3MBTL1 (0.38) | PDPK1MTORCYP2C19MAPTTMEM97 | |
| SCHEMBL402934 | 0.80 | TACR1 (0.38) | CYP2C19MAPTSIGMAR1BCHEL3MBTL1 | |
| SCHEMBL21090641 | 0.78 | SLC6A2 (0.41) | PDPK1MTORCYP2C19MAPTSLC6A2 | |
| SCHEMBL14180103 | 0.77 | PDPK1 (0.40) | PDPK1MTORCYP2C19MAPTSLC6A2 | |
| SCHEMBL10573923 | 0.77 | MAPT (0.40) | CYP2C19MAPTTMEM97SIGMAR1BCHE | |
| SCHEMBL8822994 | 0.76 | L3MBTL1 (0.50) | PDPK1MTORCYP2C19TMEM97SIGMAR1 | |
| SCHEMBL7154934 | 0.76 | MEN1 (0.41) | TMEM97SIGMAR1SLC6A2L3MBTL1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | PDPK1 4161/4885MTOR 3122/4885CYP2C19 721/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | PDPK1 4182/4885MTOR 3124/4885CYP2C19 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.